Skip to Main Content
American Flag
LABOR DAY SALE

50% off your first year of any Quiver subscription

...

Use Promo Code:

LABOR26
American Flag
×
Quiver Logo Get a Free Trial on Quiver Premium Today!
Back to News

Tenax Therapeutics Q2 Net Loss Widens to $17.8 Million

None

Tenax Therapeutics (TENX) reported second-quarter 2026 financial results and said it expects topline data from its Phase 3 LEVEL clinical trial in August 2026.

The company reported cash and cash equivalents of $118.0 million as of June 30, 2026. Tenax said $13.4 million in proceeds from warrant exercises during the quarter extended its expected cash runway through the second quarter of 2028.

  • Net loss was $17.8 million for the second quarter of 2026, compared with $10.9 million in the second quarter of 2025.
  • Research and development expenses were $12.9 million, up from $6.1 million a year earlier.
  • Selling, general and administrative expenses were $5.9 million, compared with $5.7 million in the prior-year quarter.
  • Tenax plans to present results from the Phase 3 LEVEL clinical trial in a Late-Breaking Clinical Science session at the ESC Congress 2026 in Munich.
  • The company said LEVEL-2 enrollment is expected to be completed by the end of 2027.
EARLY ACCESS
Receive TENX Data Alerts
Real-time alerts on filings, insider trades, and market signals — before everyone else.
Get Alerts →

$TENX Hedge Fund Activity

We have seen 57 institutional investors add shares of $TENX stock to their portfolio, and 3 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

Add Quiver Quantitative to your preferred sources on Google Google News Logo

Suggested Articles